摘要
背景:在神经退行性疾病中GSK3ββ与病理功能相关。这种激酶参与微管相关tau蛋白过度磷酸化,导致神经纤维缠结的聚集和形成。已清楚地表明,GSK3β是在翻译后水平调节:在tyr216激活激酶磷酸化,在Ser9磷酸化抑制其活性是必不可少的。 目的:目前,有许多的当代研究表明βGSK3可能在基因水平调控具有可能性。以往的数据显示GSK3βmRNA表达低甲基化的条件,指出了表观遗传机制βGSK3基因调控的存在。通过亚硫酸氢盐修饰人类GSK3β启动子分析,在神经母细胞瘤细胞和死后额叶皮层从AD患者(AD患者在Braak阶段I-II和阶段V-VI),允许我们来表征一个CpG岛的甲基化模式在人类GSK3β5’侧翼。 结果:分析证明整体低甲基化CpG和非CpG胞嘧啶残基在细胞和人脑(AD患者和对照组)。我们发现,βmRNA表达,GSK3只有在患者最初的AD中,在蛋白水平没有影响。另一方面,我们意外地发现与对照组相比,从AD患者皮质激活GSK3β减少在Braak阶段I-II级,而观察AD患者的阶段是相当大的增加。 结论:这些结果指出,GSK3β多动、NFT可在疾病的早期阶段来然后在关闭的最后阶段产生某种功能。
关键词: GSK3β、磷酸化、晚发型阿尔茨海默病,DNA甲基化,GSK3β基因,老年痴呆症患者,tau。
Current Alzheimer Research
Title:GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer’s Disease Patients
Volume: 14 Issue: 7
关键词: GSK3β、磷酸化、晚发型阿尔茨海默病,DNA甲基化,GSK3β基因,老年痴呆症患者,tau。
摘要: Background: The GSK3β has been associated to pathological functions in neurodegenerative diseases. This kinase is involved in hyperphosphorylation of microtubule-associated tau protein, leading to aggregation andformation of NFTs. It has clearly been shown that GSK3β is regulated at posttranslational level: phosphorylation at Tyr216 activates kinase, while phosphorylation at Ser9 is essential to inhibit its activity.
Objectives: At present, there are contradictory findings about the possibility that GSK3β may be regulated at gene level. Previous data showed overexpression of GSK3β mRNA in hypomethylating conditions, pointing out to the existence of epigenetic mechanisms responsible for GSK3β gene regulation. Analysis of human GSK3β promoter through bisulphite modification, both in neuroblastoma cells and in postmortem frontal cortex from AD patients (AD patients both at Braak stages I-II and at stages V-VI) , allowed us to characterize the methylation pattern of a putative CpG islands in human GSK3β 5’- flanking region. Results: The analysis evidenced overall hypomethylation of CpG and non-CpG cytosine residues both in cells and in human brain (AD patients and control subjects). We found that GSK3β mRNA was overexpressed only in patients with initial AD, with no effect on the levels of the protein. On the other hand, we unexpectedly observed the decrease of the inactive GSK3β in cortex from AD patients at Braak stages I-II, whereas considerable increase was observed in AD patients at stages V-VI compared to the control subjects. Conclusions: These results point out that GSK3β hyperactivity, and then NFTs formation, could come into function at an early stage of the disease and then turn off at the last stages.Export Options
About this article
Cite this article as:
GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer’s Disease Patients, Current Alzheimer Research 2017; 14 (7) . https://dx.doi.org/10.2174/1567205014666170203153325
DOI https://dx.doi.org/10.2174/1567205014666170203153325 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets Safety of Nanoparticles in Medicine
Current Drug Targets Lactoferrin Derived Peptides: Mechanisms of Action and their Perspectives as Antimicrobial and Antitumoral Agents
Mini-Reviews in Medicinal Chemistry Mitochondria: A Promising Target for Anticancer Alkaloids
Current Topics in Medicinal Chemistry Gene Expression Profile Classification: A Review
Current Bioinformatics Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design The Immunomodulation and Anti-Inflammatory Effects of Garlic Organosulfur Compounds in Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Current Pharmaceutical Design Observations on the Use of the Avian Chorioallantoic Membrane (CAM) Model in Investigations into Angiogenesis
Current Drug Targets - Cardiovascular & Hematological Disorders The Therapeutic Potential of ADAM15
Current Pharmaceutical Design Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease
Current Drug Targets Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment
Current Topics in Medicinal Chemistry Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer’s disease
Current Topics in Medicinal Chemistry Trafficking and Signaling of G Protein-Coupled Receptors in the Nervous System: Implications for Disease and Therapy
CNS & Neurological Disorders - Drug Targets The HOX Genes Network in Uro-Genital Cancers: Mechanisms and Potential Therapeutic Implications
Current Medicinal Chemistry Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Neuroglobin and Estrogen Receptors: A New Pathway of Cell Survival and Cell Death Balance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patent Selections
Recent Patents on DNA & Gene Sequences